127 related articles for article (PubMed ID: 17455665)
41. [Role of neuraminidase inhibitors for the treatment of influenza A virus infections].
Ferraris O; Escuret V; Bouscambert-Duchamp M; Lina B; Morfin F
Pathol Biol (Paris); 2010 Apr; 58(2):e69-78. PubMed ID: 20303677
[TBL] [Abstract][Full Text] [Related]
42. Detection of antiviral resistance and genetic lineage markers in influenza B virus neuraminidase using pyrosequencing.
Sheu TG; Deyde VM; Garten RJ; Klimov AI; Gubareva LV
Antiviral Res; 2010 Feb; 85(2):354-60. PubMed ID: 19887086
[TBL] [Abstract][Full Text] [Related]
43. Meeting of the WHO expert working group on surveillance of influenza antiviral susceptibility, Geneva, July 2013.
Wkly Epidemiol Rec; 2013 Nov; 88(44/45):477-82. PubMed ID: 24236332
[No Abstract] [Full Text] [Related]
44. Current challenges in the risk assessment of neuraminidase inhibitor-resistant influenza viruses.
Gubareva LV; Fry AM
J Infect Dis; 2010 Mar; 201(5):656-8. PubMed ID: 20100087
[No Abstract] [Full Text] [Related]
45. Antivirals and influenza: frequency of resistance.
Monto AS
Pediatr Infect Dis J; 2008 Oct; 27(10 Suppl):S110-2. PubMed ID: 18820569
[TBL] [Abstract][Full Text] [Related]
46. Influenza lineage extinction during the COVID-19 pandemic?
Koutsakos M; Wheatley AK; Laurie K; Kent SJ; Rockman S
Nat Rev Microbiol; 2021 Dec; 19(12):741-742. PubMed ID: 34584246
[TBL] [Abstract][Full Text] [Related]
47. Comparative thermostability analysis of zoonotic and human influenza virus A and B neuraminidase.
Evseenko VA; Svyatchenko SV; Kolosova NP; Kovrizhkina VL; Marchenko VY; Durymanov AG; Goncharova NI; Ryzhikov AB
Arch Virol; 2020 Jan; 165(1):201-206. PubMed ID: 31745716
[TBL] [Abstract][Full Text] [Related]
48. [New antiviral agents of influenza].
Miki M; Watanabe A
Nihon Rinsho; 2012 Apr; 70(4):649-54. PubMed ID: 22568148
[TBL] [Abstract][Full Text] [Related]
49. Gaseous nitric oxide reduces influenza infectivity in vitro.
Regev-Shoshani G; Vimalanathan S; McMullin B; Road J; Av-Gay Y; Miller C
Nitric Oxide; 2013 May; 31():48-53. PubMed ID: 23562771
[TBL] [Abstract][Full Text] [Related]
50. Influenza antivirals and resistance: the next 10 years?
Hurt AC; Butler J; Kelso A; Barr IG
Expert Rev Anti Infect Ther; 2012 Nov; 10(11):1221-3. PubMed ID: 23241176
[No Abstract] [Full Text] [Related]
51. Influenza nucleoprotein: promising target for antiviral chemotherapy.
Cianci C; Gerritz SW; Deminie C; Krystal M
Antivir Chem Chemother; 2012 Jul; 23(3):77-91. PubMed ID: 22837443
[TBL] [Abstract][Full Text] [Related]
52. [Development of anti-influenza drug].
Zhang T; Wang CY; Gao YW; Yang ST; Wang TC; Xia XZ
Bing Du Xue Bao; 2011 Sep; 27(5):475-80. PubMed ID: 21998961
[No Abstract] [Full Text] [Related]
53. Clinical impact of a routine, molecular, point-of-care, test-and-treat strategy for influenza in adults admitted to hospital (FluPOC): a multicentre, open-label, randomised controlled trial.
Clark TW; Beard KR; Brendish NJ; Malachira AK; Mills S; Chan C; Poole S; Ewings S; Cortes N; Nyimbili E; Presland L
Lancet Respir Med; 2021 Apr; 9(4):419-429. PubMed ID: 33285143
[TBL] [Abstract][Full Text] [Related]
54. Influenza: emerging control of an old disease.
Meissner HC
Pediatr Emerg Care; 2001 Dec; 17(6):465-70. PubMed ID: 11753198
[No Abstract] [Full Text] [Related]
55. Detection of influenza virus subtype A by polymerase chain reaction: WHO external quality assessment programme summary analysis, 2013.
Wkly Epidemiol Rec; 2014 Jan; 89(4/5):37-44. PubMed ID: 24524120
[No Abstract] [Full Text] [Related]
56. The epidemiology and antigenic characterization of influenza viruses isolated in Curitiba, South Brazil.
Vidal LR; Siqueira MM; Nogueira MB; Raboni SM; Pereira LA; Takahashi GR; Rotta I; Debur Mdo C; Dalla-Costa LM
Mem Inst Oswaldo Cruz; 2008 Mar; 103(2):180-5. PubMed ID: 18425270
[TBL] [Abstract][Full Text] [Related]
57. [Influenzavirus].
Nakajima S
Nihon Rinsho; 2003 Mar; 61 Suppl 3():508-12. PubMed ID: 12718019
[No Abstract] [Full Text] [Related]
58. A two-tiered model for simulating the ecological and evolutionary dynamics of rapidly evolving viruses, with an application to influenza.
Koelle K; Khatri P; Kamradt M; Kepler TB
J R Soc Interface; 2010 Sep; 7(50):1257-74. PubMed ID: 20335193
[TBL] [Abstract][Full Text] [Related]
59. Inhibition of cellular RNA methyltransferase abrogates influenza virus capping and replication.
Tsukamoto Y; Hiono T; Yamada S; Matsuno K; Faist A; Claff T; Hou J; Namasivayam V; Vom Hemdt A; Sugimoto S; Ng JY; Christensen MH; Tesfamariam YM; Wolter S; Juranek S; Zillinger T; Bauer S; Hirokawa T; Schmidt FI; Kochs G; Shimojima M; Huang YS; Pichlmair A; Kümmerer BM; Sakoda Y; Schlee M; Brunotte L; Müller CE; Igarashi M; Kato H
Science; 2023 Feb; 379(6632):586-591. PubMed ID: 36758070
[TBL] [Abstract][Full Text] [Related]
60. Antiviral activity of Epimedium koreanum Nakai water extract against influenza viruses.
Cho WK; Ma JY
Biomed Pharmacother; 2022 Feb; 146():112581. PubMed ID: 34965505
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
